152 related articles for article (PubMed ID: 35146837)
41. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
43. Candida urinary tract infections in adults.
Odabasi Z; Mert A
World J Urol; 2020 Nov; 38(11):2699-2707. PubMed ID: 31654220
[TBL] [Abstract][Full Text] [Related]
44. [Efficacy of micafungin sodium on fungal infection in critical care].
Tateishi Y; Hirasawa H; Oda S; Nakanishi K; Kitamura S; Aikawa N
Nihon Ishinkin Gakkai Zasshi; 2006; 47(4):293-7. PubMed ID: 17086162
[TBL] [Abstract][Full Text] [Related]
45. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
[TBL] [Abstract][Full Text] [Related]
46. Candiduria in catheterized intensive care unit patients: emerging microbiological trends.
Jain M; Dogra V; Mishra B; Thakur A; Loomba PS; Bhargava A
Indian J Pathol Microbiol; 2011; 54(3):552-5. PubMed ID: 21934219
[TBL] [Abstract][Full Text] [Related]
47. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study.
Viscoli C; Bassetti M; Castagnola E; Cesaro S; Menichetti F; Ratto S; Tascini C; Giacobbe DR
BMC Infect Dis; 2014 Dec; 14():725. PubMed ID: 25551699
[TBL] [Abstract][Full Text] [Related]
48. First report on echinocandin resistant Polish Candida isolates.
Mroczyńska M; Brillowska-Dabrowska A
Acta Biochim Pol; 2019 Sep; 66(3):361-364. PubMed ID: 31518088
[TBL] [Abstract][Full Text] [Related]
49. [Nosocomial urinary tract infections by Candida species].
de Oliveira RD; Maffei CM; Martinez R
Rev Assoc Med Bras (1992); 2001; 47(3):231-5. PubMed ID: 11723503
[TBL] [Abstract][Full Text] [Related]
50. Candida urinary tract infections--epidemiology.
Sobel JD; Fisher JF; Kauffman CA; Newman CA
Clin Infect Dis; 2011 May; 52 Suppl 6():S433-6. PubMed ID: 21498836
[TBL] [Abstract][Full Text] [Related]
51. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
52. Fluconazole versus micafungin for initial antifungal prophylaxis against Candida in pancreas transplant recipients: A comparative study of two consecutive periods.
López-Medrano F; Muñoz de la Espada M; Pérez-Jacoiste Asín MA; Fernández-Ruiz M; Herrero-Martínez JM; Alonso-Carrillo J; San Juan R; Rodríguez-Goncer I; Andrés A; González E; Manrique A; Justo I; Marcacuzco A; Loinaz C; Jiménez C; Lumbreras C; Aguado JM
Mycoses; 2022 May; 65(5):517-525. PubMed ID: 35262977
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
54. [Why might micafungin be the drug of choice in pediatric patients?].
Ramos Amador JT; Prieto Tato L; Guillén Martín S
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():23-8. PubMed ID: 21420573
[TBL] [Abstract][Full Text] [Related]
55. Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.
Villaescusa T; Vázquez L; Bergua JM; García J; Romero A; Olave MT; García Belmonte D; Queipo de Llano MP;
Rev Esp Quimioter; 2020 Feb; 33(1):44-48. PubMed ID: 31865649
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
[TBL] [Abstract][Full Text] [Related]
57. [Fungal (Candida) infections in critically ill children in the intensive care unit].
Marquez Aguirre MP; Diaz Pena R; Fernandez Lucio O; Garcia R
Drugs Today (Barc); 2008 Nov; 44 Suppl 4():33-41. PubMed ID: 19536372
[TBL] [Abstract][Full Text] [Related]
58. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
[TBL] [Abstract][Full Text] [Related]
59. Five-year cross-sectional study to determine the burden of
Konje ET; Kizenga O; Charco NJ; Kibwana UO; Shango N; Tarimo F; Mushi MF
BMJ Open; 2023 Dec; 13(12):e074833. PubMed ID: 38154909
[TBL] [Abstract][Full Text] [Related]
60. Predictive factors and prognostic value of candiduria in critically-ill patients with solid and hematological malignancies.
Chaari A; Munir A; Sharaf A; Khairy A; Kauts V; Erdem H
J Mycol Med; 2023 Mar; 33(1):101353. PubMed ID: 36442396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
